Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations

[1]  R. Yunus,et al.  Treatment of Hypertension in Patients with Coronary Artery Disease , 2016 .

[2]  G. Mancia,et al.  The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140 mmHg rather than below 120 mmHg , 2016, Blood pressure.

[3]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[4]  A. Rodgers,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[5]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[6]  G. Parati,et al.  Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses , 2015, Journal of hypertension.

[7]  Christopher M O'Connor,et al.  Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement From the American Heart Association, American College of Cardiology, and American Society of Hypertension , 2015 .

[8]  Christopher M O'Connor,et al.  Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement From the American Heart Association, American College of Cardiology, and American Society of Hypertension , 2015, Hypertension.

[9]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs – Overview and meta-analyses , 2015, Journal of hypertension.

[10]  D. Levy,et al.  Does Low Diastolic Blood Pressure Contribute to the Risk of Recurrent Hypertensive Cardiovascular Disease Events?: The Framingham Heart Study , 2015, Hypertension.

[11]  S. Yusuf,et al.  Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease , 2015, Hypertension.

[12]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials , 2014, Journal of hypertension.

[13]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels – overview and meta-analyses of randomized trials , 2014, Journal of hypertension.

[14]  Harry Hemingway,et al.  Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people , 2014, The Lancet.

[15]  J. Cutler,et al.  Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial , 2014, Diabetes Care.

[16]  Yoav Ben-Shlomo,et al.  Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. , 2014, Journal of the American College of Cardiology.

[17]  Jeroen J. Bax,et al.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. , 2013, European heart journal.

[18]  A. Dominiczak,et al.  2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. , 2013, Journal of hypertension.

[19]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[20]  Alan D. Lopez,et al.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[21]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.

[22]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[23]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[24]  T. Lauer,et al.  Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .

[25]  Martin G Myers,et al.  Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial , 2011, BMJ : British Medical Journal.

[26]  C. Cannon,et al.  What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?: Relationship of Blood Pressure and Cardiovascular Events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 Trial , 2010, Circulation.

[27]  Heather M. Tavel,et al.  Blood Pressure Trajectories and Associations With Treatment Intensification, Medication Adherence, and Outcomes Among Newly Diagnosed Coronary Artery Disease Patients , 2010, Circulation. Cardiovascular quality and outcomes.

[28]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[29]  B. Williams.  Hypertension and the "J-curve". , 2009, Journal of the American College of Cardiology.

[30]  G. Panjrath,et al.  The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? , 2009, Journal of the American College of Cardiology.

[31]  K. Gould,et al.  Does coronary flow trump coronary anatomy? , 2009, JACC. Cardiovascular imaging.

[32]  N J Wald,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[33]  M. Law.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009 .

[34]  S. Yusuf,et al.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2008, The Lancet.

[35]  S. Yusuf,et al.  Thrombolytics for PE and right ventricular dysfunction , 2008, The Lancet.

[36]  R. Bache,et al.  Regulation of coronary blood flow during exercise. , 2008, Physiological reviews.

[37]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[38]  H. Okayama,et al.  Possible link between large artery stiffness and coronary flow velocity reserve , 2007, Heart.

[39]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[40]  G. Mancia,et al.  Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study , 2007, Hypertension.

[41]  M. O'Rourke,et al.  Mechanical factors in arterial aging: a clinical perspective. , 2007, Journal of the American College of Cardiology.

[42]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[43]  Nico Westerhof,et al.  Cross-talk between cardiac muscle and coronary vasculature. , 2006, Physiological reviews.

[44]  E. Tuzcu,et al.  Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. , 2006, Journal of the American College of Cardiology.

[45]  S. Yusuf,et al.  Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.

[46]  G. Mancia,et al.  Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.

[47]  I. Meredith,et al.  Aortic stiffness affects the coronary blood flow response to percutaneous coronary intervention. , 2006, American journal of physiology. Heart and circulatory physiology.

[48]  Thomas Weber,et al.  Increased arterial wave reflections predict severe cardiovascular events in patients undergoing percutaneous coronary interventions. , 2005, European heart journal.

[49]  A. Mendez,et al.  Aortic Pressure Augmentation Predicts Adverse Cardiovascular Events in Patients With Established Coronary Artery Disease , 2005, Hypertension.

[50]  François Gueyffier,et al.  Systolic and Diastolic Blood Pressure Lowering as Determinants of Cardiovascular Outcome , 2005, Hypertension.

[51]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[52]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[53]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[54]  P. Poole‐Wilson,et al.  Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial , 2004, The Lancet.

[55]  R. Califf,et al.  Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. , 2004, American heart journal.

[56]  J. Gardin,et al.  Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. , 2004, Journal of the American College of Cardiology.

[57]  Eric J Topol,et al.  Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. , 2004, JAMA.

[58]  K. Fox.  The EUROPA trial , 2003, The Lancet.

[59]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[60]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[61]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[62]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[63]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[64]  James D Cameron,et al.  Large artery stiffness predicts ischemic threshold in patients with coronary artery disease. , 2002, Journal of the American College of Cardiology.

[65]  M. O'Rourke,et al.  Quantification of glyceryl trinitrate effect through analysis of the synthesised ascending aortic pressure waveform , 2002, Heart.

[66]  P. Armstrong,et al.  Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. , 2001, European heart journal.

[67]  Paolo Verdecchia,et al.  Different Prognostic Impact of 24-Hour Mean Blood Pressure and Pulse Pressure on Stroke and Coronary Artery Disease in Essential Hypertension , 2001, Circulation.

[68]  Martin G. Larson,et al.  Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging?: The Framingham Heart Study , 2001, Circulation.

[69]  M. Safar,et al.  Should diastolic and systolic blood pressure be considered for cardiovascular risk evaluation: a study in middle-aged men and women. , 2001, Journal of the American College of Cardiology.

[70]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[71]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[72]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[73]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[74]  R. Collins,et al.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. , 1998, Circulation.

[75]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[76]  M. Moser,et al.  Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. , 1996, Journal of the American College of Cardiology.

[77]  S. Cobbe,et al.  Coronary haemodynamics in left ventricular hypertrophy. , 1996, Heart.

[78]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[79]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction , 1994, The Lancet.

[80]  Y. Sugishita,et al.  Decreased aortic compliance aggravates subendocardial ischaemia in dogs with stenosed coronary artery. , 1992, Cardiovascular research.

[81]  J. Cruickshank.  The role of coronary perfusion pressure. , 1992, European heart journal.

[82]  R. D'Agostino,et al.  Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. , 1991, BMJ.

[83]  A. Moss,et al.  Effects of diltiazem on long-term outcome after acute myocardial infarction in patients with and without a history of systemic hypertension. The Multicenter Diltiazem Postinfarction Trial Research Group. , 1991, The American journal of cardiology.

[84]  M. Guazzi,et al.  Upward Shift of the Lower Range of Coronary Flow Autoregulation in Hypertensive Patients With Hypertrophy of the Left Ventricle , 1991, Circulation.

[85]  C. Mulrow,et al.  The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? , 1991, JAMA.

[86]  J. Canty.  Coronary Pressure‐Function and Steady‐State Pressure‐Flow Relations During Autoregulation in the Unanesthetized Dog , 1988, Circulation research.

[87]  J. Cruickshank,et al.  BENEFITS AND POTENTIAL HARM OF LOWERING HIGH BLOOD PRESSURE , 1987, The Lancet.

[88]  A. J. Dunning,et al.  Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. , 1988, British heart journal.

[89]  I. Stewart.  RELATION OF REDUCTION IN PRESSURE TO FIRST MYOCARDIAL INFARCTION IN PATIENTS RECEIVING TREATMENT FOR SEVERE HYPERTENSION , 1979, The Lancet.

[90]  C. Bloor,et al.  Characteristics of coronary blood flow and transmural distribution in miniature pigs. , 1978, The American journal of physiology.

[91]  I. Salti,et al.  PHENYTOIN IN BENIGN INSULINOMA , 1976, The Lancet.